Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated. The incidence of sorafenib-associated high-grade (grade 3-4) HTN was 6.0% (95% CI 4.7-7.3) in a total of 4722 patients from 55 trials of sorafenib as a single agent. Sorafenib-treated patients (4878 subjects from 13 randomized trials) had a significantly higher risk of high-grade HTN ). Subgroup analysis revealed a significantly higher RR of high-grade HTN in patients receiving sorafenib as a single agent compared with patients receiving concomitant chemotherapy or immunotherapy (P ¼ 0.0076). The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) than those with non-RCC cancer (Po0.0001) as well as patients treated with sorafenib for a longer duration than those treated for a shorter duration (P ¼ 0.003). The use of sorafenib is associated with a significantly higher risk of high-grade HTN compared with control.
INTRODUCTION
Sorafenib is an oral multi-kinase inhibitor with significant activity against Raf, a serine/threonine kinase that mediates cell proliferation as well as several receptor tyrosine kinases, including vascular endothelial growth factor (VEGF) receptor-2 and -3, plateletderived growth factor receptor-beta, Flt-3 and c-KIT, which are implicated in neovascularization and tumor progression. In preclinical models, sorafenib has been shown to induce tumor cell death and inhibit angiogenesis. 1, 2 Currently, the Food and Drug Administration has approved sorafenib for patients with advanced renal cell carcinoma (RCC) and unresectable hepatocellular carcinoma (HCC). 3 The toxicity profiles of VEGF-targeted tyrosine kinase inhibitors, including sunitinib and sorafenib, are unique compared with the adverse effects typically associated with cytotoxic anticancer therapies. For instance, previous studies have demonstrated an increased risk of developing hand-foot skin reaction, bleeding, arterial thromboembolism and hematological toxicities with these former agents. [4] [5] [6] [7] [8] [9] Additionally, hypertension (HTN) has been associated with treatment with VEGF-tyrosine kinase inhibitors. 10 Wu et al. 11 performed a meta-analysis of four randomized controlled trials (RCTs), four single-arm phase II trials and one expanded-access program of sorafenib conducted between 2006 and 2007. The results demonstrated a significantly higher risk of all-grade HTN in patients administered sorafenib, with an relative risk (RR) of 6.11 (95% confidence interval (CI) 2.44-15.32, Po0.001), and an overall all-grade HTN incidence of 23.4% (95% CI 16.0-32.9%) and high-grade HTN incidence of 5.7% (2.5-12.6%).
However, as Rini 12 noted in a comment on this report, there were several limitations to the analysis.
First, their meta-analysis may have underestimated the incidence of HTN associated with sorafenib because approximately 75% of the patients included in their analysis were derived from the expanded-access program, which did not include standardized toxicity data collection and reporting. Second, although the RR of all-grade HTN was significant, this finding was limited by the small sample size of patients included for analysis (n ¼ 548 for the sorafenib arm from two RCTs; n ¼ 541 for the control arm). Finally, the RR of high-grade HTN (grade 3-4) was not assessed. Thus, the overall risk and incidence of high-grade HTN with sorafenib treatment has not yet been fully elucidated. Since this previous meta-analysis was performed, many additional large, randomized clinical trials have been completed. Therefore, we conducted an up-to-date systemic review and meta-analysis of RCTs to assess the risk of high-grade HTN with sorafenib treatment.
BAY43-9006 from the American Society of Clinical Oncology conferences held between January 2006 and August 2012 were manually searched. An independent search of the Web of Science, Embase and Cochrane electronic databases was also performed to ensure that there were no additional studies. In cases of duplicate publications, only the most complete, recent and updated report of the clinical trial was included. Finally, the most updated package insert from sorafenib was reviewed to identify relevant information. 3 
Study selection
Clinical trials that met the following criteria were included: (1) phase II and III trials in patients with cancer; (2) participants assigned to treatment with sorafenib; and (3) events or event rate and sample size available for allgrade or high-grade HTN (X grade 3). For incidence analysis, trials that assigned participants to sorafenib monotherapy were used to define the incidence of HTN associated with sorafenib as a single agent. For RR analysis, we included trials that randomly assigned participants to either sorafenib and best supportive care versus best supportive care with or without placebo or sorafenib plus concurrent chemotherapy and/or immunotherapy versus chemotherapy and/or immunotherapy alone. Phase I trials were excluded because of the different drug dosages as well as the small number of patients in these trials. Independent reviewers (TF and AL) screened reports that included the key term by their titles and abstracts for relevance. Then, full texts of the relevant articles were retrieved to assess eligibility. The references of relevant reports were also reviewed manually.
Data extraction and clinical end points
Data extraction was independently performed by two investigators (TF and AL). The following information was recorded for each study: first author's name, year of publication, trial phase, underlying malignancy, number of patients enrolled, treatment arms, median age, median treatment duration, median progression-free survival, number of patients available for analysis and the number of events of all-and high-grade HTN (Table 1) . Any discrepancies between reviewers were resolved by consensus. The number of patients evaluable for toxicity was utilized as the number analyzed for each trial, unless this was not indicated in the publication, in which case the number of patients enrolled was utilized. When trials using a crossover design were identified, only data available from before the crossover were used. In cases where this was not available, those studies were excluded. The HTN events in most of the included trials were recorded according to version 2 or 3 of the Common Terminology Criteria for Adverse Events (CTCAE), which are similar in terms of grading HTN events as follows: grade 1, asymptomatic, transient (o24 h) increase in blood pressure (BP) of 420 mm Hg (diastolic) or to 4150/100 mm Hg if previously within normal limits, intervention not indicated; grade 2, recurrent or persistent (424 h) or symptomatic increase by 420 mm Hg (diastolic) or to 4150/100 mm Hg if previously within normal limits, monotherapy might be indicated; grade 3, more than one drug needed for treatment or for a more intensive treatment than used previously; and grade 4, life-threatening consequences (for example, hypertensive crisis). 14 The new CTCAE version 4 HTN scale, which is aligned with the seventh report of the Joint National Committee (JNC 7) criteria, was used in one included trial. 15, 16 Statistical analysis The summary incidence, RR and corresponding 95% CIs of all-grade (grade 1-4) and high-grade (grades 3 and 4) HTN were calculated. The primary objective of this study was to assess the association between treatment with sorafenib and the development of high-grade HTN in cancer patients in RCTs that directly compared sorafenib and controls. We calculated the RRs and CIs with data extracted only from randomized controlled studies and compared the incidence of HTN in patients assigned to sorafenib with those assigned to control treatment in the same trial. To calculate the 95% CIs, the variance of the log-transformed study-specific RR was derived using the delta method. To calculate the incidence, the number of patients with HTN (both high-grade and all-grade) and the number of patients receiving sorafenib alone were extracted from the selected single-arm and clinical RCTss.
The proportion of patients with adverse outcomes and 95% CIs was derived from each trial. For studies reporting zero events in any arm, continuity corrections of 0.5 were adopted to calculate the RR and variance. For the calculation of RRs and summary incidence, we used random-or fixed-effects models depending on the heterogeneity of included studies. We assessed statistical heterogeneity among the proportions of the included trials included in our meta-analysis with Cochrane's Q statistic, and we quantified inconsistency with the I 2 statistic (100% Â (Q À df)/Q). An assumption of homogeneity was considered invalid for P-values o0.10. When substantial heterogeneity was not observed, the pooled estimate calculated based on the fixed-effects model was reported using the inverse variance method. When substantial heterogeneity was observed, the pooled estimate calculated based on the random-effects model was reported using the DerSimonian and Laird method, which considers both within-and between-study variations. The publication bias regarding the primary end point (RR of high-grade HTN) was evaluated using Begg's and Egger's tests. A two-tailed P-value of o0.05 was considered statistically significant. Statistical analysis was performed using the program Review Manager 5.1 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) and the Comprehensive Meta Analysis program (Version 2, Biostat, Englewood, NJ, USA).
RESULTS

Search results
Our search strategy yielded 374 potentially relevant citations, including 212 articles on sorafenib from Medline and 162 abstracts on sorafenib from the ASCO online database. The selection process excluded 148 citations; the reasons for study exclusion are shown in Figure 1 . From the abstracts presented during ASCO meetings, we identified two abstracts with full-text publications that were not previously identified in the Medline databases. Thus, a total of 64 clinical trials were considered eligible for the metaanalysis, including 11 phase III trials and 53 phase II trials.
Study quality Randomized treatment allocation sequences were generated in all the included phase III trials. Of the 53 phase II trials, 10 trials involved randomized treatment allocation, while 43 trials were single-arm trials. Of the 21 RCTs, 11 trials were double-blind placebo controlled, 1 trial had placebo as a control and 9 trials had active treatment as the control arms. The HTN events in the included trials were recorded according to version 2, 3 or 4 of the CTCAE. Three trials utilized version 2, 45 trials utilized version 3, one trial utilized version 4 and the remainder of the trials did not specify the CTCAE version. For quality analysis purposes, we calculated the incidence in randomized versus nonrandomized trials and phase II versus III trials. We found no statistically significant difference between these subgroups (data not shown).
Population characteristics A total of 8474 patients (sorafenib: 6088; control: 2386) were available for the meta-analysis. HTN was not listed as a preexisting condition in any of these trials. The baseline Eastern Cooperative Oncology Group performance status for the majority of patients was between 0 and 1. Based on the eligibility criteria of most of the trials, patients with impaired renal, hepatic, hematological or cardiac function were excluded. The most common underlying malignancies represented were renal cell cancer (16 trials), non-small cell lung cancer (8 trials), thyroid cancer (6 trials), HCC (6 trials), prostate cancer (5 trials), gastrointestinal stromal tumor (3 trials), breast cancer (3 trials) and melanoma (3 trials). The baseline characteristics and the number of all-grade and high-grade HTN events in each trial are presented in Table 1 .
Overall incidence of HTN For the incidence analysis, we considered only arms with sorafenib as a single agent and excluded arms with concomitant chemotherapy and/or immunotherapy due to the potential for increased BP associated with these treatments. Thus, a total of 4722 patients from both randomized and nonrandomized studies (eight phase III and 47 phase II trials) were included. A total of Risk of hypertension with sorafenib T Funakoshi et al Risk of hypertension with sorafenib T Funakoshi et al 4178 patients were included for all-grade HTN events and 4722 were included for high-grade events. This numerical difference was because seven trials reported only high-grade events, and the others reported both all-grade and high-grade events. All-grade HTN occurred in 1000 of 4178 patients, resulting in an incidence of 23.1% (95% CI 19.3-26.9). High-grade HTN occurred in 379 of 4722 patients, resulting in an incidence of 6.0% (95% CI 4.7-7.3%). The test for heterogeneity was significant for all-grade and high-grade HTN (Po0.1), and the random-effects model was used.
RR of HTN events
For the meta-analysis of the overall RR of all-grade and high-grade HTN, 13 randomized trials with sorafenib in only one of the arms in addition to similar best supportive care, chemotherapy and/or immunotherapy in both the arms were available (7 phase III studies and 6 phase II studies including 4878 patients). The RR of all-grade and high-grade HTN associated with sorafenib versus control was 3.06 (95% CI 2.04-4.59; Po0.00001) and 3.20 (95% CI 2.19-4.68; Po0.00001), respectively ( Figure 2 ). The random-effects model was used because there was significant heterogeneity in the RR analysis of all-grade HTN (Po0.1). The test for heterogeneity was not significant for high-grade HTN (P40.1), and the fixed-effects model was used.
Subgroup analyses Due to the potential risk of increased BP with chemotherapeutic or immunotherapeutic agents, we explored the impact of control arm treatment on the RRs of high-grade HTN with sorafenib. Of the 13 randomized trials included for RR analyses, four trials explored sorafenib as a single agent, and 9 trials used sorafenib in combination with chemotherapy and/or immunotherapy. Interestingly, the effect size was significantly greater in the RR analysis of high-grade HTN considering only the trials that used sorafenib as a single agent compared with RR considering only the trials that used concomitant chemotherapy or immunotherapy (ratio of RR, 4.00; 95% CI, 1.44-10.83; P ¼ 0.0076) (Figure 3) . The incidence and RR of high-grade HTN were further analyzed by common tumor types, such as RCC, HCC and non-small cell lung cancer, and duration of treatment because patients with different tumors may be at different risk for HTN, and the duration of treatment may affect risk of HTN. Interestingly, the incidence of high-grade HTN associated with sorafenib was significantly higher in patients with RCC than in patients with non-RCC cancer (Po0.0001). Finally, patients enrolled into trials with a duration of treatment longer than the median duration of treatment of all trials (3.8 months) demonstrated a significantly higher incidence of high-grade HTN compared with those enrolled into trials with a shorter duration of treatment (P ¼ 0.003; Table 2 ).
Publication bias
We found no evidence of publication bias for the primary end point of this study (RR of high-grade HTN) by either Egger's (P ¼ 0.34) or Begg's test (P ¼ 0.58).
DISCUSSION
To the best of our knowledge, this is the first meta-analysis to demonstrate a significantly increased risk of high-grade HTN associated with the multi-targeted tyrosine kinase inhibitor sorafenib in patients with cancer, with an incidence of 6.0% (95% CI 4.7-7.3) and RR of 3.20 (95% CI 2.19-4.68; Po0.00001).
Our exploratory subgroup analysis demonstrated a significantly higher risk of high-grade HTN in patients treated with sorafenib as a single agent than in patients treated with concomitant Figure 1 . CONSORT diagram; selection process for the trials.
Risk of hypertension with sorafenib T Funakoshi et al chemotherapy or immunotherapy. The reason for this difference is unclear. However, because the incidence of high-grade HTN in both sorafenib and control arms was higher in the combination therapy group than in the sorafenib monotherapy group, the agents utilized in both arms of these trials might be related to increased BP, thereby diminishing the difference in HTN frequency among the treatment arms. Our findings show that the incidence of high-grade HTN is significantly higher in patients with RCC compared with non-RCC cancers. This finding is consistent with the analysis of sunitinib, for which a higher incidence of HTN has been observed in RCC patients compared with non-RCC patients. 10 One possible explanation is that VEGF expression is higher in patients with RCC than in non-RCC patients, which may result in a more substantial impairment of endothelial function. 17 In addition, patients with RCC might have a greater risk of HTN than non-RCC patients as a result of renal insufficiency from previous nephrectomy. 18 We also showed that patients treated with sorafenib for a longer duration had a significantly higher incidence of high-grade HTN than those treated for a shorter Risk of hypertension with sorafenib T Funakoshi et al duration. However, no difference was observed in all-grade HTN incidence for patients in trials with a longer versus shorter duration of treatment (data not shown). This finding suggests that the development of high-grade HTN may be dose-dependent and may have a distinct mechanism from the development of all-grade HTN.
HTN is a class-type adverse effect of VEGF inhibitors. Although the exact mechanisms underlying the development of HTN are not clear, the mechanism of HTN induced by sorafenib seems to be directly related to its anti-VEGF effect, resulting in reduced nitric oxide (NO) and prostacyclin as well as rarefaction (that is, decreased number of microvessels). A previous study showed that VEGF has a significant role in maintaining basal vascular tone by regulating NO and prostacyclin synthesis. 19, 20 Indeed, rapid hypotension was induced by infusions of VEGF through the increased production of NO and subsequent vasodilation. 21, 22 Maitland et al. 23 reported that the majority of BP elevation events occurred during the first day of sorafenib therapy, and a further increase occurred until steady-state plasma drug concentrations were first reached.
This finding suggests that vasoconstriction resulting from the inhibition of endothelial-derived vasodilatory factors, such as NO, is the primary mechanism of the acute rise in BP. 23 In addition, preclinical and human evidence has suggested a second slower mechanism of BP elevation from microvascular rarefaction. VEGF signaling is essential for the angiogenic cascade, proliferation, survival, permeability responses and endothelial differentiation. 24 Additionally, endothelial cell apoptosis is induced by VEGF signaling pathway inhibition, causing a reduced number of arterioles and capillaries in humans. 25, 26 Both vasoconstriction and microvascular rarefaction result in increased peripheral vascular resistance, which leads to HTN.
The recognition and management of HTN in sorafenib-treated patients are important because uncontrolled HTN can not only lead to serious cardiovascular events but may also necessitate discontinuation of sorafenib. 27, 28 Furthermore, severe HTN due to sorafenib may be associated with reversible posterior leukoencephalopathy syndrome. 29, 30 VEGFR tyrosine kinase inhibitors have improved clinical outcomes in malignancies, and cancer patients are expected to live longer. Thus, the adequate and aggressive management of mild-to-moderate HTN associated with sorafenib is also essential to prevent long-term complications from HTN.
Currently, there are no evidence-based guidelines for the management of VEGF inhibitor-induced HTN, because there is a lack of controlled studies addressing the subject. Most authors agree that pre-existing HTN should be controlled before the start of sorafenib therapy. A previous study showed that HTN is detectable as early as the first day of therapy and more readily detected when steady-state concentrations of sorafenib are first reached at approximately day 7. Because the magnitude of BP elevation is not associated with patient age, weight, sex, race or baseline BP, it is difficult to predict the amplitude of this increase. 23 Thus, BP should be monitored weekly during the first 6 weeks of sorafenib therapy, as recommended by the package insert.
In general, VEGF inhibitor-induced HTN should be treated in the manner outlined in the JNC 7 guidelines. 16 However, some preclinical and clinical data suggest the optimal selection and use of antihypertensive medications. Angiotensin-converting enzyme inhibitors have been proposed as an effective treatment of this HTN. Angiotensin II has been shown to enhance VEGF production and VEGF receptor expression in vitro. The tumor environment produces angiotensin locally, which contributes to tumor angiogenesis and tumor progression. 31 Indeed, studies in mouse models have shown that angiotensin-converting enzyme inhibitors reduce tumor growth by blocking angiogenesis. 32, 33 Moreover, Nagasawa et al. 34 administered sorafenib alone or in combination with captopril to rats for 4 weeks. Concurrent treatment with captopril resulted in a significant decrease in BP and albuminuria compared with sorafenib alone. Calcium channel blockers have also been used to successfully treat VEGF inhibitorrelated HTN. Because sorafenib is primarily metabolized through CYP3A4, nondihydropyridine calcium channel blockers, such as verapamil and diltiazem, which are CYP3A4 inhibitors, can substantially increase the plasma concentration of sorafenib. 3 Thus, dihydropyridine calcium channel blockers, such as nifedipine and amlodipine besylate, are the preferred choices. In addition, nifedipine was effective at reversing HTN induced by cediranib in a phase II randomized clinical trial. 35 Because anti-VEGF agents are considered to cause HTN primarily through decreasing endothelial NO production, nitrates that restore vasodilatation through the NO signaling pathway would seem to be rational antihypertensive therapies. 36 However, a potential concern is that the concurrent use of nitrates with VEGF inhibitors could compromise antitumor efficacy, as NO is known to mediate VEGF-induced angiogenesis. Additional studies of antihypertensive agents in the setting of HTN related to angiogenesis inhibitors are required to guide therapy.
As BP elevation is likely related to successful inhibition of the VEGF signaling pathway, HTN appears to be a pharmacodynamic marker of the therapeutic effect of angiogenesis inhibitors. Several investigators have studied the relationship between HTN and the outcome of VEGF signaling pathway inhibition therapy. Estfan et al. 37 retrospectively assessed whether HTN was a positive predictive marker of overall survival in patients taking sorafenib for advanced HCC. Patients with any grade of HTN while on treatment, according to CTCAE v3.0 (15 of 39 evaluable patients), lived longer than those without HTN, with a median overall survival of 18.2 months (95% CI 4.5-35.7) and 4.5 months (95% CI 2.4-7.3), respectively (P ¼ 0.0165). Szmit et al. 38 also performed 39 showed that patients with mean increases in diastolic BP (Ä dBP) X15 mm Hg (n ¼ 18) per ambulatory BP monitoring performed on cycle 1 day 15 had a higher objective response rate than those with Ä dBP o15 mm Hg (n ¼ 36; 61 versus 53%). These results indicate that HTN is a biomarker of tumor response and improved survival. However, the best approach in using this information to optimize the administration of VEGF inhibitors is still unclear.
Our study has several potential limitations. As with any metaanalysis, the results described here are affected by the limitations of individual clinical trials that were selected for this meta-analysis. First, the incidence of HTN may have been underestimated in clinical trials that used CTCAE version 2 or 3. In both these versions, HTN is defined as BP 4150/100 mm Hg or an increase in diastolic BP420 mm Hg. By contrast, in the more commonly accepted guideline (JNC 7), patients are considered hypertensive if the BP is 4140/90 mm Hg. In addition, there is an overlap with the definition between CTCAE grade 2 and 3 HTN because grade 2 is defined as persistent, recurrent or symptomatic BP increase, and grade 3 is based on the need for multidrug antihypertensive therapy. Our findings of high-grade HTN could be affected by this overlap. Second, baseline HTN was not described in the included trials. This could lead to an overestimation of new-onset HTN. However, the presence of baseline all-grade and high-grade HTN was low, at 4.3% (95% CI, 2.6 to 6.0%) and 0.9% (95% CI, 0.4 to 1.5%), respectively, as calculated in patients who received the control treatment in our meta-analysis. In addition, it is unlikely that the baseline HTN biased the RR, because it was calculated from randomized controlled clinical trials that directly compared arms treated with and without sorafenib.
In conclusion, our study has shown that sorafenib is associated with a significant risk of developing high-grade HTN in cancer patients. The risk of high-grade HTN is higher for patients with renal cell cancer and for patients treated with sorafenib for a long duration. This study provides further evidence that clinicians should routinely monitor BP in patients treated with sorafenib for the early detection and proper treatment of HTN to prevent cardiovascular complications and improve patient outcomes.
What is known about this topic
Unique toxicities associated with vascular endothelial growth factor receptor-targeted therapies, such as hand-foot syndrome and hypertension (HTN), have been reported. A previous meta-analysis of clinical trials of sorafenib demonstrated a significantly higher risk of all-grade HTN in patients treated with sorafenib.
What this study adds
Our updated meta-analysis of clinical trials of sorafenib revealed that sorafenib is associated with a significant increase in the risk of highgrade HTN. Subgroup analysis showed a significantly higher RR of high-grade HTN in patients receiving sorafenib monotherapy compared with patients receiving sorafenib in combination with other agents. The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) compared with those with non-RCC cancer and in patients treated with sorafenib for a longer duration compared with those treated for a shorter duration.
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